Department of Obstetrics and Gynecology, Bhumibol Adulyadej Hospital, Royal Thai Air Force, Bangkok, Thailand.
Department of Preclinical Sciences, Faculty of Medicine, Thammasat University, Pathumthani, Thailand.
Biomed Res Int. 2022 Feb 13;2022:9449036. doi: 10.1155/2022/9449036. eCollection 2022.
The aim of this study was to compare maternal and neonatal outcomes between sublingual misoprostol and oxytocin on stimulating labor in term premature rupture of membranes (PROM) in pregnant women. . This randomized single-blind control trial was conducted at Bhumibol Adulyadej Hospital (BAH), Royal Thai Air Force, Bangkok, Thailand, between September 2020 and February 2021. Subjects were term pregnant women who had PROM and came to BAH for delivery. Participants were allocated into study (misoprostol) and control (oxytocin) groups. The study and control groups were, respectively, administered sublingual misoprostol and intravenous oxytocin to induce labor. Induction time and second stage of labor were recorded. Neonatal outcomes and maternal and fetal complications were also recorded and analyzed.
A total of 170 women were enrolled and equally divided into study and control groups. Mean maternal age, body mass index, parity, gestational age, and bishop score of both groups were comparable. Induction time of the study group was statistically shorter than the control group (338 and 399 min, respectively). Duration of active phase (450/427 min) and the second stage (19/21 min) of labor between study and control groups were not significantly different. Cesarean section delivery rate of study was lower than the control group (13.3 and 28.8%, = 0.002). Intrapartum complications, neonatal outcomes, and intra- and postpartum complications among both groups were not significantly differentiated. There was no instance of postpartum hemorrhage or uterine rupture in the present study.
Induction time and cesarean section rates of sublingual misoprostol group were significantly lower than the intravenous oxytocin group in full-term PROM pregnancy.
本研究旨在比较舌下含服米索前列醇与缩宫素在足月胎膜早破(PROM)孕妇引产中的母儿结局。这是一项在泰国曼谷泰国皇家空军 Bhumibol Adulyadej 医院(BAH)进行的随机单盲对照试验,时间为 2020 年 9 月至 2021 年 2 月。研究对象为足月 PROM 并到 BAH 分娩的孕妇。将参与者分为研究(米索前列醇)和对照(缩宫素)组。研究组和对照组分别给予舌下含服米索前列醇和静脉滴注缩宫素引产。记录引产时间和第二产程。记录新生儿结局和母婴并发症,并进行分析。
共纳入 170 例孕妇,平均分为研究组和对照组。两组产妇年龄、体重指数、产次、孕周和 Bishop 评分无统计学差异。研究组引产时间明显短于对照组(分别为 338 分钟和 399 分钟)。两组活跃期(450/427 分钟)和第二产程(19/21 分钟)持续时间无统计学差异。研究组剖宫产率低于对照组(13.3%和 28.8%, = 0.002)。两组产时并发症、新生儿结局及产褥期并发症无统计学差异。本研究中无产后出血或子宫破裂病例。
在足月 PROM 妊娠中,舌下含服米索前列醇组的引产时间和剖宫产率明显低于静脉滴注缩宫素组。